Jun 17, 2020
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
May 26, 2020
Insmed to Present at Two June Conferences
Apr 06, 2020
The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%
Apr 03, 2020
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
Mar 05, 2020
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class And Segment Forecasts, 2020 - 2027
Feb 25, 2020
Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting
Jan 15, 2020
Visiongain Publishes Global Pulmonary Arterial Hypertension Market 2019-2029 Report
Nov 05, 2019
Insmed to Present at Two November Conferences
Sep 12, 2019
Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application
Jun 26, 2019
Orenitram (treprostinil; United Therapeutics) Market Overview - Newer Brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Poses Tough Competition in the Oral Prostacyclin Class
Jun 26, 2019
Remodulin (treprostinil; United Therapeutics/Mochida) Overview: United Therapeutics is Developing Three New Formulations of Remodulin to Overcome Administration Difficulties
Jun 06, 2019
Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
May 29, 2019
The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026
Apr 01, 2019
Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
Oct 22, 2018
Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension
Oct 02, 2018
Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
Aug 28, 2018
Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
Jul 31, 2018
United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®
Jul 24, 2018
China Latanoprost Market Report 2018-2022
Jun 13, 2018
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension